Discovery of genetic interactions in cancer
$2,274,811ZIAFY2021CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 39078448Paper 36873924Paper 35610202Paper 35597871Paper 35474866Paper 35338126Paper 35196484Paper 34983745Paper 34555175Paper 34340996Paper 33857424Paper 33811070Paper 33523837Paper 33500247Paper 33498690Paper 33318707Paper 33257848Paper 31358840Paper 31340155Paper 31047779Paper 30773340Paper 30573518Paper 30501643Paper 30404913Paper 30209241Paper 30131853Paper 30127394Paper 30100185Paper 30065243
Abstract
This approach provides a basis for new combination-based therapeutic strategies improving the effectiveness of existing cancer therapies by identifying and targeting drug resistance pathways. Going forward in this line of research, having just established our laboratory recently, we intend to explore two main paths: (a) precision medicine - inferring patient specific GI-mediated drug response by analyzing the transcriptomics of their tumors, and (b) drug development - identifying new SL-based drug targets, combined with their SL-derived patient stratification profiles.
View original record on NIH RePORTER →